MA34483B1 - Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante - Google Patents

Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Info

Publication number
MA34483B1
MA34483B1 MA35688A MA35688A MA34483B1 MA 34483 B1 MA34483 B1 MA 34483B1 MA 35688 A MA35688 A MA 35688A MA 35688 A MA35688 A MA 35688A MA 34483 B1 MA34483 B1 MA 34483B1
Authority
MA
Morocco
Prior art keywords
treatment
hypertension
prevention
heart failure
anticoagulant therapy
Prior art date
Application number
MA35688A
Other languages
English (en)
Inventor
Diego Albrecht
Priyamvada Chandra
Sven Godtfredsen
Pierre Jordaan
Martin Lefkowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34483(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34483B1 publication Critical patent/MA34483B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions pharmaceutiques pour le traitement de l'hypertension et/ou la prévention ou le traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante à l'aide d'un ou de plusieurs composés qui sont thérapeutiquement efficaces mais n'ont pas d'impact sur le ou les effets pharmacocinétiques ou pharmacodynamiques de l'anticoagulant, tels que la warfarine.
MA35688A 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante MA34483B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37641710P 2010-08-24 2010-08-24
PCT/US2011/048542 WO2012027237A1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante

Publications (1)

Publication Number Publication Date
MA34483B1 true MA34483B1 (fr) 2013-08-01

Family

ID=44543868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35688A MA34483B1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Country Status (18)

Country Link
US (2) US20130158088A1 (fr)
EP (1) EP2608784B1 (fr)
JP (1) JP2013536230A (fr)
KR (1) KR101864865B1 (fr)
CN (1) CN103079554A (fr)
AU (1) AU2011293648B2 (fr)
BR (1) BR112013004192A2 (fr)
CA (1) CA2807830C (fr)
CL (1) CL2013000513A1 (fr)
ES (1) ES2702529T3 (fr)
GT (1) GT201300047A (fr)
MA (1) MA34483B1 (fr)
MX (1) MX341174B (fr)
PH (1) PH12013500231A1 (fr)
RU (1) RU2564941C2 (fr)
SG (1) SG187755A1 (fr)
TW (1) TW201208678A (fr)
WO (1) WO2012027237A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2667643C2 (ru) * 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
EP3038653A1 (fr) * 2013-08-26 2016-07-06 Novartis AG Nouvelle utilisation
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
DK3229799T3 (en) * 2014-12-08 2019-02-11 Crystal Pharmatech Co Ltd CRYSTALLINIC FORMS OF SUPRAMOLECULATED TRINATRIUM COMPLEX, INCLUDING VALSARTAN AND AHU-377, AND PROCEDURES THEREOF
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
WO2017218418A1 (fr) * 2016-06-13 2017-12-21 The Board Of Regents Of The University Of Texas System Compositions et procédés de modélisation de l'insuffisance cardiaque à fraction d'éjection conservée
EP3840746A1 (fr) 2018-08-23 2021-06-30 Novartis AG Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (fr) 1990-02-19 1996-02-28 Ciba-Geigy Ag Composés acylés
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US6869357B2 (en) * 2001-12-19 2005-03-22 Igt Methods of conducting games of chance and gaming devices with multiple pay lines
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US7857515B2 (en) * 2007-06-15 2010-12-28 S.C. Johnson Home Storage, Inc. Airtight closure mechanism for a reclosable pouch
KR101589317B1 (ko) * 2007-11-06 2016-01-28 노파르티스 아게 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Also Published As

Publication number Publication date
US20140329872A1 (en) 2014-11-06
SG187755A1 (en) 2013-03-28
TW201208678A (en) 2012-03-01
WO2012027237A1 (fr) 2012-03-01
CA2807830A1 (fr) 2012-03-01
CL2013000513A1 (es) 2014-08-29
RU2013112859A (ru) 2014-09-27
RU2564941C2 (ru) 2015-10-10
MX341174B (es) 2016-08-10
EP2608784B1 (fr) 2018-09-19
JP2013536230A (ja) 2013-09-19
ES2702529T3 (es) 2019-03-01
EP2608784A1 (fr) 2013-07-03
PH12013500231A1 (en) 2017-08-09
US20130158088A1 (en) 2013-06-20
CA2807830C (fr) 2018-04-03
BR112013004192A2 (pt) 2016-05-10
MX2013002212A (es) 2013-05-09
GT201300047A (es) 2014-07-08
KR101864865B1 (ko) 2018-06-05
KR20130095754A (ko) 2013-08-28
AU2011293648A1 (en) 2013-03-21
AU2011293648B2 (en) 2015-02-12
CN103079554A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA51530B1 (fr) Composés cycliques fondus
MA40290A1 (fr) Agents immunorégulateurs
NZ727849A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA42145A (fr) Triazoles agonistes du récepteur apj
MA54231B1 (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
TN2010000154A1 (fr) Composition destinee a la regulation du metabolism des lipides
MA37808A1 (fr) Composés et leurs utilisations thérapeutiques
MA39972B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA38959A1 (fr) Modulateurs du facteur b du complément
MA35804B1 (fr) Modulation de l'expression du virus de l'hepatite b (vhb)
MA34474B1 (fr) Agonistes de gpr40
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA54386B1 (fr) Modulateurs de trex1
MA32360B1 (fr) Thérapie pour cancer hépatique
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA29723B1 (fr) Composes
MA43294A1 (fr) Sels et promédicaments de 1-méthyl -d-tryptophane
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2018049003A8 (fr) Composés inhibiteurs de sialidase anti-fibrotique et leurs méthodes d'utilisation
FR2974300B1 (fr) Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c pour la prevention et/ou le traitement de desordres pigmentaires
EP2870971A4 (fr) Médicament pour la prévention/le traitement d'une maladie oculaire